Recent chatter on X about Eli Lilly and Company (LLY) has been dominated by the latest clinical trial data for its oral weight-loss drug, orforglipron, which has sparked significant debate. Despite the company reporting a strong Q2 earnings beat with a 61% rise in adjusted EPS and 38% revenue growth, posts on X highlight disappointment over the drug's trial results, leading to a sharp pre-market drop in stock price. This unexpected setback has shifted focus away from the company's otherwise robust financial performance.
The discussion on X also reflects on Eli Lilly's broader portfolio, with some users pointing to earlier positive sentiment around tirzepatide and its potential to reduce heart failure risks as a counterbalance to the current negativity. Frustration is evident as many express concern over the impact of the orforglipron data on future growth prospects in the competitive weight-loss drug market. The tone remains dynamic, with investors keenly awaiting further updates on the company's strategic moves.
Note: This discussion summary was generated from an AI condensation of post data.
Eli Lilly and Company Congressional Stock Trading
Members of Congress have traded $LLY stock 18 times in the past 6 months. Of those trades, 5 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $LLY stock by members of Congress over the last 6 months:
- REPRESENTATIVE JONATHAN L. JACKSON has traded it 2 times. They made 1 purchase worth up to $50,000 on 04/21 and 1 sale worth up to $50,000 on 06/03.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. sold up to $15,000 on 05/30.
- REPRESENTATIVE MARJORIE TAYLOR GREENE has traded it 2 times. They made 2 purchases worth up to $30,000 on 05/14, 05/05 and 0 sales.
- REPRESENTATIVE JOSH GOTTHEIMER has traded it 5 times. They made 1 purchase worth up to $15,000 on 05/01 and 4 sales worth up to $60,000 on 05/13, 04/09, 03/10, 02/19.
- REPRESENTATIVE JEFFERSON SHREVE sold up to $250,000 on 05/12.
- REPRESENTATIVE BRUCE WESTERMAN has traded it 2 times. They made 1 purchase worth up to $15,000 on 03/03 and 1 sale worth up to $15,000 on 04/21.
- SENATOR TOMMY TUBERVILLE sold up to $50,000 on 04/15.
- REPRESENTATIVE DAN NEWHOUSE sold up to $15,000 on 04/11.
- REPRESENTATIVE ROBERT BRESNAHAN sold up to $15,000 on 04/08.
- REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 04/07.
- SENATOR RON WYDEN sold up to $100,000 on 02/10.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Eli Lilly and Company Insider Trading Activity
Eli Lilly and Company insiders have traded $LLY stock on the open market 63 times in the past 6 months. Of those trades, 0 have been purchases and 63 have been sales.
Here’s a breakdown of recent trading of $LLY stock by insiders over the last 6 months:
- ENDOWMENT INC LILLY has made 0 purchases and 57 sales selling 814,452 shares for an estimated $699,963,820.
- DANIEL SKOVRONSKY (EVP, CSO & Pres. LRL & LLY Imm) has made 0 purchases and 3 sales selling 5,000 shares for an estimated $4,316,064.
- DONALD A ZAKROWSKI (SVP, Finance, & CAO) has made 0 purchases and 2 sales selling 2,000 shares for an estimated $1,534,650.
- ILYA YUFFA (EVP & President, LLY Int'l) sold 1,250 shares for an estimated $936,550
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Eli Lilly and Company Hedge Fund Activity
We have seen 1,904 institutional investors add shares of Eli Lilly and Company stock to their portfolio, and 1,678 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PNC FINANCIAL SERVICES GROUP, INC. added 50,002,551 shares (+97.5%) to their portfolio in Q1 2025, for an estimated $41,297,606,896
- GAMMA INVESTING LLC removed 14,848,396 shares (-99.9%) from their portfolio in Q2 2025, for an estimated $11,574,770,133
- PROFICIO CAPITAL PARTNERS LLC removed 5,183,974 shares (-99.6%) from their portfolio in Q1 2025, for an estimated $4,281,495,966
- CAPITAL RESEARCH GLOBAL INVESTORS added 4,989,952 shares (+46.4%) to their portfolio in Q1 2025, for an estimated $4,121,251,256
- VANGUARD GROUP INC added 4,975,395 shares (+6.7%) to their portfolio in Q1 2025, for an estimated $4,109,228,484
- GQG PARTNERS LLC removed 2,705,511 shares (-59.7%) from their portfolio in Q1 2025, for an estimated $2,234,508,590
- FMR LLC removed 2,066,580 shares (-6.8%) from their portfolio in Q1 2025, for an estimated $1,706,809,087
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Eli Lilly and Company Analyst Ratings
Wall Street analysts have issued reports on $LLY in the last several months. We have seen 6 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 07/11/2025
- UBS issued a "Buy" rating on 05/02/2025
- HSBC issued a "Reduce" rating on 04/28/2025
- Cantor Fitzgerald issued a "Overweight" rating on 04/22/2025
- Morgan Stanley issued a "Overweight" rating on 04/09/2025
- Goldman Sachs issued a "Buy" rating on 04/08/2025
- Wells Fargo issued a "Overweight" rating on 03/05/2025
To track analyst ratings and price targets for Eli Lilly and Company, check out Quiver Quantitative's $LLY forecast page.
Eli Lilly and Company Price Targets
Multiple analysts have issued price targets for $LLY recently. We have seen 7 analysts offer price targets for $LLY in the last 6 months, with a median target of $975.0.
Here are some recent targets:
- Seamus Fernandez from Guggenheim set a target price of $942.0 on 07/11/2025
- Terence Flynn from Morgan Stanley set a target price of $1135.0 on 07/10/2025
- Trung Huynh from UBS set a target price of $1050.0 on 05/02/2025
- Rajesh Kumar from HSBC set a target price of $700.0 on 04/28/2025
- Carter Gould from Cantor Fitzgerald set a target price of $975.0 on 04/22/2025
- Asad Haider from Goldman Sachs set a target price of $888.0 on 04/08/2025
- Mohit Bansal from Wells Fargo set a target price of $1100.0 on 03/05/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
